MedTrace Logo

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

NCT04323631 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2020-06-30

No results posted yet for this study

Summary

This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk for complications. We aim to demonstrate decrease in progression to severe pneumonia and hospital related complications among patients who are treated with HCQ compared to patients who are not.

Conditions

Interventions

DRUG

Hydroxychloroquine

Oral

OTHER

The control group will not receive hydroxychloroquine

The control group will not receive hydroxychloroquine

Sponsors & Collaborators

  • Rabin Medical Center

    collaborator OTHER

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Paul · Rambam MC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-04-30
Completion
2020-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04323631 on ClinicalTrials.gov